• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.卡介苗膀胱灌注治疗对Ta T1期高级别膀胱癌二次经尿道切除术后的疗效
Yonago Acta Med. 2019 Jun 20;62(2):191-197. doi: 10.33160/yam.2019.06.003. eCollection 2019 Jun.
2
Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.在第二次经尿道切除术后进行卡介苗治疗可显著降低新诊断的高级别T1期膀胱癌患者的复发率。
BMC Urol. 2016 Feb 27;16:8. doi: 10.1186/s12894-016-0126-x.
3
Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.原发性 T1 期膀胱癌二次经尿道电切术后行膀胱内卡介苗治疗。
Int J Clin Oncol. 2018 Oct;23(5):951-956. doi: 10.1007/s10147-018-1292-5. Epub 2018 May 14.
4
Results of second transurethral resection for high-grade T1 bladder cancer.高级别T1期膀胱癌二次经尿道切除术的结果
Urol Ann. 2016 Jan-Mar;8(1):10-5. doi: 10.4103/0974-7796.163798.
5
Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.经膀胱内卡介苗治疗的高级别 T1 膀胱癌患者，二次经尿道电切术时间对肿瘤学结果的影响。
World J Urol. 2020 Dec;38(12):3161-3167. doi: 10.1007/s00345-020-03108-z. Epub 2020 Feb 15.
6
A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.卡介苗膀胱灌注联合经尿道切除术与单纯经尿道切除术治疗Ta和T1期膀胱癌的系统评价
BJU Int. 2001 Aug;88(3):209-16. doi: 10.1046/j.1464-410x.2001.02306.x.
7
Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.T1 期高级别膀胱癌患者在二次 TUR 时代发生膀胱内复发的危险因素。
Jpn J Clin Oncol. 2013 Apr;43(4):404-9. doi: 10.1093/jjco/hyt016. Epub 2013 Feb 26.
8
Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?高级别T1期膀胱癌是否总是需要重复经尿道切除术？
Front Oncol. 2019 Jun 4;9:465. doi: 10.3389/fonc.2019.00465. eCollection 2019.
9
Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.高危非肌层浸润性膀胱癌患者接受维持性膀胱内卡介苗治疗时，首次与第二次经尿道膀胱肿瘤切除术间隔时间对复发率和进展率的意义。
BJU Int. 2015 Nov;116(5):721-6. doi: 10.1111/bju.13102. Epub 2015 May 11.
10
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.经膀胱内卡介苗治疗的非肌肉浸润性膀胱癌患者，再次经尿道电切术对复发率和进展率的影响。
J Urol. 2014 Feb;191(2):341-5. doi: 10.1016/j.juro.2013.08.022. Epub 2013 Aug 20.

本文引用的文献

1
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.膀胱癌临床实践指南（2017 年第 5 版），NCCN 肿瘤学临床实践指南
J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.
2
Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.在第二次经尿道切除术后进行卡介苗治疗可显著降低新诊断的高级别T1期膀胱癌患者的复发率。
BMC Urol. 2016 Feb 27;16:8. doi: 10.1186/s12894-016-0126-x.
3
Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?T1 高级别膀胱癌患者的预后因素和结果：我们能否识别需要早期行膀胱切除术的患者？
BJU Int. 2012 Apr;109(7):1026-30. doi: 10.1111/j.1464-410X.2011.10462.x. Epub 2011 Aug 24.
4
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.EAU 指南：非肌层浸润性膀胱尿路上皮癌，2011 年更新版。
Eur Urol. 2011 Jun;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.
5
Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial.新诊断的 T1 期尿路上皮癌患者行常规二次经尿道电切术对复发、进展率和疾病特异性生存率的长期影响：一项前瞻性随机临床试验。
Eur Urol. 2010 Aug;58(2):185-90. doi: 10.1016/j.eururo.2010.03.007. Epub 2010 Mar 19.
6
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.对新诊断的高级别 T1（以前为 T1G3）膀胱癌的治疗策略进行的最新批判性分析。
Eur Urol. 2010 Jan;57(1):60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1.
7
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.当代一组临床 T1 膀胱癌重新分期患者的临床结局。
Eur Urol. 2009 Dec;56(6):903-10. doi: 10.1016/j.eururo.2009.07.005. Epub 2009 Jul 17.
8
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.非肌层浸润性膀胱癌（Ta、T1和Tis期）管理指南：2007年更新版
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
9
Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?T1期膀胱癌再次经尿道切除术能否筛选出适合立即行膀胱切除术的患者？
J Urol. 2007 Jan;177(1):75-9; discussion 79. doi: 10.1016/j.juro.2006.08.070.
10
Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.膀胱内灌注卡介苗能否降低浅表性膀胱癌患者的复发率？一项随机试验的荟萃分析。
Urology. 2006 Jun;67(6):1216-23. doi: 10.1016/j.urology.2005.12.014.

卡介苗膀胱灌注治疗对Ta T1期高级别膀胱癌二次经尿道切除术后的疗效

Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.

作者信息

Kimura Yusuke, Honda Masashi, Morizane Shuichi, Hikita Katsuya, Isoyama Tadahiro, Ono Koji, Koumi Tsutomu, Takahashi Chihiro, Takenaka Atsushi

机构信息

Division of Urology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.

Torrori Prefectual Central Hospital, Tottori 680-0901, Japan.

出版信息

Yonago Acta Med. 2019 Jun 20;62(2):191-197. doi: 10.33160/yam.2019.06.003. eCollection 2019 Jun.

DOI:10.33160/yam.2019.06.003
PMID:31320823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6584257/
Abstract

BACKGROUND

To evaluate the efficacy of Bacilli Calmette-Guerin (BCG) induction instillation therapy after second transurethral resection (TUR) in stage Ta T1 high-grade bladder cancer.

METHODS

We performed a retrospective analysis of 49 consecutive new onset Ta T1 high-grade bladder cancer patients treated with second TUR at our affiliated institutions. Residual cancer rate, intravesical recurrence-free survival (RFS), and risk factors related to RFS were evaluated by univariate and multivariate Cox proportional hazard model analyses.

RESULTS

Thirty-one patients received BCG therapy after the second TUR (BCG group), and 18 patients were treated with second TUR alone (no BCG group). There were statistically significant differences in the RFS rates between the two groups, ( = 0.037). BCG therapy was the only factor predictive of intravesical recurrence after second TUR in both univariate and multivariate analyses. After the second TUR, BCG therapy significantly decreased intravesical recurrence in the patients with residual tumors ( = 0.014). However, there was no significant difference in intravesical recurrence in the patients with no residual tumors between the two groups ( = 0.359).

CONCLUSION

BCG therapy after second TUR significantly decreased intravesical recurrence of residual tumors found at the second TUR.

摘要

背景

评估卡介苗（BCG）诱导灌注疗法在Ta T1期高级别膀胱癌二次经尿道膀胱肿瘤电切术（TUR）后的疗效。

方法

我们对在我们附属机构接受二次TUR治疗的49例新诊断的Ta T1期高级别膀胱癌患者进行了回顾性分析。通过单因素和多因素Cox比例风险模型分析评估残余癌发生率、膀胱内无复发生存率（RFS）以及与RFS相关的危险因素。

结果

31例患者在二次TUR后接受了BCG治疗（BCG组），18例患者仅接受了二次TUR治疗（无BCG组）。两组的RFS率存在统计学显著差异（=0.037）。在单因素和多因素分析中，BCG治疗是二次TUR后膀胱内复发的唯一预测因素。二次TUR后，BCG治疗显著降低了有残余肿瘤患者的膀胱内复发率（=0.014）。然而，两组中无残余肿瘤患者的膀胱内复发率无显著差异（=0.359）。

结论

二次TUR后进行BCG治疗可显著降低二次TUR时发现的残余肿瘤的膀胱内复发率。